244 related articles for article (PubMed ID: 26888114)
1. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Wang D; Berglund A; Kenchappa RS; Forsyth PA; Mulé JJ; Etame AB
Sci Rep; 2016 Feb; 6():21710. PubMed ID: 26888114
[TBL] [Abstract][Full Text] [Related]
2. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
Wang D; Berglund AE; Kenchappa RS; MacAulay RJ; Mulé JJ; Etame AB
Sci Rep; 2017 Aug; 7(1):9350. PubMed ID: 28839258
[TBL] [Abstract][Full Text] [Related]
3. A Novel Role of BIRC3 in Stemness Reprogramming of Glioblastoma.
Wu Q; Berglund AE; MacAulay RJ; Etame AB
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008722
[TBL] [Abstract][Full Text] [Related]
4. Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.
Hu X; Meng Y; Xu L; Qiu L; Wei M; Su D; Qi X; Wang Z; Yang S; Liu C; Han J
Cell Death Dis; 2019 Feb; 10(2):104. PubMed ID: 30718461
[TBL] [Abstract][Full Text] [Related]
5. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
6. miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Qian Z; Zhou S; Zhou Z; Yang X; Que S; Lan J; Qiu Y; Lin Y
Oncol Rep; 2017 Nov; 38(5):2941-2950. PubMed ID: 29048680
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
9. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
[TBL] [Abstract][Full Text] [Related]
10. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Piro G; Giacopuzzi S; Bencivenga M; Carbone C; Verlato G; Frizziero M; Zanotto M; Mina MM; Merz V; Santoro R; Zanoni A; De Manzoni G; Tortora G; Melisi D
Br J Cancer; 2015 Sep; 113(6):878-85. PubMed ID: 26291056
[TBL] [Abstract][Full Text] [Related]
11. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
13. RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Yeom SY; Nam DH; Park C
Mol Cancer Ther; 2014 Dec; 13(12):3049-61. PubMed ID: 25313011
[TBL] [Abstract][Full Text] [Related]
14. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Jahan N; Lee JM; Shah K; Wakimoto H
Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic pathways and glioblastoma treatment.
Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Lu VM; Jue TR; McDonald KL
Sci Rep; 2020 Oct; 10(1):18156. PubMed ID: 33097778
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced homotypic cell fusions of innately resistant glioblastoma cells mediate their sustained survival and recurrence.
Kaur E; Rajendra J; Jadhav S; Shridhar E; Goda JS; Moiyadi A; Dutt S
Carcinogenesis; 2015 Jun; 36(6):685-95. PubMed ID: 25863126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
